Skip to content
2000
image of The Diagnostic and Prognostic Potential of Serum Taurine and PUMA in Staging Colorectal Cancer Patients

Abstract

Introduction

Ranked as the third most diagnosed cancer globally, colorectal cancer (CRC) is the seventh most prevalent cancer in Egypt. This study aimed to assess the levels of taurine (Tau), carcinoembryonic antigen (CEA), and p53 upregulated modulator of apoptosis (PUMA) in CRC patients.

Methods: We conducted a pilot study involving 70 patients with CRC. Serum Tau was measured using ELISA, CEA was evaluated by immunohistochemistry (IHC), and PUMA expression was assessed using quantitative real-time PCR (qPCR). All measurements were taken before surgery, one week after surgery, and one month later.

Results

Tau levels were significantly lower in adenocarcinoma groups (G1, G2, and G3) and in the malignant metastatic group compared with the control and inflammatory groups ( < 0.001). Tau levels increased in G1, G2, and G3 patients one week and one month after surgery. PUMA expression after surgery was higher than before surgery in G1, G2, and G3 adenocarcinoma groups, while it was absent in the metastatic group. The specificity of the Tau test before surgery, one week after, and one month after was 53.33%, 76.92%, and 46.67%, respectively. The specificity of the PUMA test was 76.92% before surgery and 71.43% after surgery. CEA levels were significantly higher in adenocarcinoma (G1 and G2) compared with control and inflammatory groups, whereas CEA staining intensity was significantly decreased in adenocarcinoma (G1 and G2) compared with these groups ( < 0.001).

Discussion

PUMA expression tends to be lower in advanced CRC stages and increases after surgery, supporting its potential role in tumor suppression and prognosis. Taurine shows variable levels among CRC patients and may aid in non-invasive cancer staging; its lower serum levels are associated with more advanced disease, and levels rise following surgical removal of the tumor.

Conclusion

This study highlights PUMA as a potential prognostic indicator for CRC. Tau levels may also hold diagnostic value and could contribute to the development of non-invasive screening methods for early CRC detection, particularly within the Egyptian population, which remains underrepresented in current research. Such results may be used to stimulate future patents on CRC biomarker-based diagnostics and customized treatment methods.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/biot/10.2174/0118722083419407251202120006
2026-02-27
2026-03-10

  • From This Site

    /content/journals/biot/10.2174/0118722083419407251202120006
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Elhadidy A. Haydara T. Increase young age incidence of colorectal carcinoma among cohort of Egyptian population. Al-Azhar Int Med J 2022 3 1 71 75 10.21608/aimj.2022.105010.1650
    [Google Scholar]
  2. Wolf A.M.D. Fontham E.T.H. Church T.R. Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 2018 68 4 250 281 10.3322/caac.21457 29846947
    [Google Scholar]
  3. Shaukat A. Kahi C.J. Burke C.A. Rabeneck L. Sauer B.G. Rex D.K. ACG clinical guidelines: Colorectal cancer screening 2021. Am. J. Gastroenterol. 2021 116 3 458 479 10.14309/ajg.0000000000001122 33657038
    [Google Scholar]
  4. Siegel R.L. Miller K.D. Goding Sauer A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020 70 3 145 164 10.3322/caac.21601 32133645
    [Google Scholar]
  5. Lin J.S. Perdue L.A. Henrikson N.B. Bean S.I. Blasi P.R. Screening for colorectal cancer. JAMA 2021 325 19 1978 1998 10.1001/jama.2021.4417 34003220
    [Google Scholar]
  6. Bonnington S.N. Rutter M.D. Surveillance of colonic polyps: Are we getting it right? World J. Gastroenterol. 2016 22 6 1925 1934 10.3748/wjg.v22.i6.1925 26877600
    [Google Scholar]
  7. Kow A.W.C. Hepatic metastasis from colorectal cancer. J. Gastrointest. Oncol. 2019 10 6 1274 1298 10.21037/jgo.2019.08.06 31949948
    [Google Scholar]
  8. Hamers P.A.H. Elferink M.A.G. Stellato R.K. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data. Int. J. Cancer 2021 148 2 296 306 10.1002/ijc.33200 32638384
    [Google Scholar]
  9. Rawla P. Sunkara T. Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz. Gastroenterol. 2019 14 2 89 103 10.5114/pg.2018.81072 31616522
    [Google Scholar]
  10. Shi J Løberg M, Kalager M, et al Effect of colonoscopy screening on risks of colorectal cancer and related death: Instrumental variable estimation of per-protocol effects. Eur. J. Epidemiol. 2025 40 4 419 425 10.1007/s10654‑025‑01209‑w 40278966
    [Google Scholar]
  11. Grobbee E.J. Wisse P.H.A. Schreuders E.H. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals. Cochrane Libr. 2022 2022 6 CD009276 10.1002/14651858.CD009276.pub2 35665911
    [Google Scholar]
  12. Jakubauskas M. Jasiūnas E. Strupas K. Poskus T. The impact of follow-up colonoscopy on survival in a fecal immunochemical test–based colorectal cancer screening program: A nationwide study. Dis. Colon Rectum 2025 68 7 899 906 10.1097/DCR.0000000000003771 40202196
    [Google Scholar]
  13. Vettore L. Westbrook R.L. Tennant D.A. New aspects of amino acid metabolism in cancer. Br. J. Cancer 2020 122 2 150 156 10.1038/s41416‑019‑0620‑5 31819187
    [Google Scholar]
  14. Agouza I.M.E. Saad A.H. Mahfouz A.A. Hamdy K. Serum taurine level in relation to ophthalmoscopic examination as early marker for diabetic retinopathy. Clin Med Biochem 2017 3 1 1 8 10.4172/2471‑2663.1000124
    [Google Scholar]
  15. Wooldrage K. Robbins E.C. Duffy S.W. Cross A.J. Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet Gastroenterol. Hepatol. 2024 9 9 811 824 10.1016/S2468‑1253(24)00190‑0 39038482
    [Google Scholar]
  16. Stratified Sampling | Definition, Guide & Examples. 2020 Available from: https://www.scribbr.com/methodology/stratified-sampling/
  17. Tong G. Xu W. Zhang G. The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer - A retrospective cohort study. Cancer Med. 2018 7 11 5327 5338 10.1002/cam4.1814 30302946
    [Google Scholar]
  18. Yilmaz A. Onen H.I. Alp E. Menevse S. Real-time PCR for gene expression analysis. In: Polymera Chain Reaction. IntechOpen 2012 229 254 10.5772/37356
    [Google Scholar]
  19. Samir S. El-Ashry M. Soliman W. Hassan M. Urinary biomarkers analysis as a diagnostic tool for early detection of pancreatic adenocarcinoma: Molecular quantification approach. Comput. Biol. Chem. 2024 112 January 108171 10.1016/j.compbiolchem.2024.108171 39159599
    [Google Scholar]
  20. Badawi H. Abass M. Hamam O. Diab M. El Said M. Ismail A. Molecular and in-situ hybridization detection of human papillomavirus genotypes among Egyptian patients with bladder cancer. Int J Pharm Res 2018 10 4 402 411 10.31838/ijpr/2018.10.04.056
    [Google Scholar]
  21. Kabel A.M. Tumor markers of breast cancer: New prospectives. J Oncol Sci 2017 3 1 5 11 10.1016/j.jons.2017.01.001
    [Google Scholar]
  22. Yu J. Wang Z. Kinzler K.W. Vogelstein B. Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 2003 100 4 1931 1936 10.1073/pnas.2627984100 12574499
    [Google Scholar]
  23. Samir S. Human DNA mutations and their impact on genetic disorders. Recent Pat. Biotechnol. 2024 18 4 288 315 10.2174/0118722083255081231020055309 37936448
    [Google Scholar]
  24. Amira El-Hakim H. El-Agouza M. El-Shimy R.A. Mohammed H.G. El-Gendy H.A.A. The prospect of using serum taurine level as a potential biomarker for early detection of colorectal carcinoma and its correlation with other prognostic markers. Case Med Res 2019 5
    [Google Scholar]
  25. El-agouza I.M. Ghaffar M.M.A. Abd-allah A.A. El Gendy H.A. Comparison between serum taurine and specific tumor markers for early detection and diagnosis of HCC in Egyptian patients. World J Adv Healthc Res 2019 3 1 99 101
    [Google Scholar]
  26. Deng L. Chang D. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps. US Patent 20210189499A1 2023
    [Google Scholar]
  27. Raftery D.R. Djukovic D. Gu H. Zhu J. Biomarkers for detecting and monitoring colon cancer. US Patent 10274496B2 2016
    [Google Scholar]
  28. Mohammad RM Muqbil I Lowe L Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 2015 35 Suppl (0) S78 S103. 10.1016/j.semcancer.2015.03.001 25936818
    [Google Scholar]
  29. Zhang L. Yu J. Role of apoptosis in colon cancer biology, therapy, and prevention. Curr. Colorectal Cancer Rep. 2013 9 4 331 340 10.1007/s11888‑013‑0188‑z 24273467
    [Google Scholar]
  30. Huang Y. Liu N. Liu J. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle 2019 18 24 3442 3455 10.1080/15384101.2019.1688951 31726940
    [Google Scholar]
  31. Kim J. Yu L. Chen W. Wild-type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation. Cancer Cell 2019 35 2 191 203.e8 10.1016/j.ccell.2018.12.012 30712844
    [Google Scholar]
/content/journals/biot/10.2174/0118722083419407251202120006
Loading
The Diagnostic and Prognostic Potential of Serum Taurine and PUMA in Staging Colorectal Cancer Patients
Bentham Science Publishers ; https://doi.org/10.2174/0118722083419407251202120006
/content/journals/biot/10.2174/0118722083419407251202120006
/content/journals/biot/10.2174/0118722083419407251202120006
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: qPCR ; PUMA ; ELISA ; IHC ; taurine ; Colorectal cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test